Health and Healthcare

Health and Healthcare Articles

All Health and Healthcare Articles

5867 Articles

Chris Lange | Oct 12, 2018 at 10:20 AM EDT

Why Corium Shares Are Booming

Corium shares jumped on Friday after the company announced that it entered into a definitive merger agreement under which Gurnet…

Chris Lange | Oct 11, 2018 at 1:20 PM EDT

How Compugen Is Weathering Thursday’s Storm

Compugen shares pushed higher on Thursday after it was announced that Bristol-Myers Squibb will make a $12 million equity investment…

Chris Lange | Oct 11, 2018 at 12:05 PM EDT

CRISPR Wins FDA Approval for Human Trials

CRISPR Therapeutics shares made a handy gain on Thursday after the company announced a key FDA decision concerning its collaboration…

Chris Lange | Oct 10, 2018 at 12:20 PM EDT

Meet Ionis Pharma’s Newest Collaboration

Ionis Pharmaceuticals shares were relatively flat on Wednesday after the company announced a new collaboration with Roche to develop IONIS-FB-LRx…

Chris Lange | Oct 10, 2018 at 10:50 AM EDT

Why AcelRx Is Jumping Despite FDA Update

AcelRx shares made a solid gain on Wednesday despite a less-than-favorable update from the FDA. However, there is a vote…

Chris Lange | Oct 10, 2018 at 9:10 AM EDT

Short Sellers Run for Cover From Major Pharma

The September 28 short interest data have been compared with the previous figures, and short interest in these selected pharmaceutical…

Chris Lange | Oct 10, 2018 at 8:20 AM EDT

Short Sellers Back Off Major Biotechs

The September 28 short interest data have been compared with the previous report, and short interest in most of the…

Chris Lange | Oct 9, 2018 at 10:20 AM EDT

Mylan’s Mapi Collaboration for Multiple Sclerosis Doesn’t Seem to Be Paying Off

Mylan shares hit a 52-week low after Mapi Pharma announced midstage results from its multiple sclerosis trial.

Chris Lange | Oct 9, 2018 at 9:15 AM EDT

Can This Clinical Hold Stop Affimed’s Momentum?

Affimed shares took a big step back early on Tuesday after the company announced that it has placed its AFM11…

Chris Lange | Oct 8, 2018 at 11:45 AM EDT

Akcea Stumbles Over Newest Board Addition

Akcea Therapeutics shares pulled back on Monday after the company announced a big change to its board of directors.

Chris Lange | Oct 8, 2018 at 10:45 AM EDT

Exelixis Initiates Key Late-Stage Cancer Trial

Exelixis shares dipped on Monday after the company announced that it has initiated a late-stage trial in patients with radioiodine-refractory…

Chris Lange | Oct 6, 2018 at 7:55 AM EDT

Major Biopharma Catalysts to Watch For in October

Here 24/7 Wall St. includes a calendar of a few of the biggest companies expecting clinical trial and FDA updates…

Chris Lange | Oct 5, 2018 at 10:15 AM EDT

KemPharm: The Secondary Offering From Hell

KemPharm shares were crushed on Friday after the company announced that it would be conducting a secondary offering.

Chris Lange | Oct 5, 2018 at 9:45 AM EDT

SI-Bone Announces Potential Pricing for IPO

Medical device company SI-Bone intends to list 6 million shares in an initial public offering valued up to more than…

Chris Lange | Oct 4, 2018 at 1:45 PM EDT

Why Vaxart’s New Flu Vaccine Is So Great

Vaxart shares more than doubled on Thursday after the company announced positive results from the midstage trial of its influenza…

1 … 117 118 119 120 121 … 392

Health and Healthcare Articles

All Health and Healthcare Articles

Why Corium Shares Are Booming

How Compugen Is Weathering Thursday’s Storm

CRISPR Wins FDA Approval for Human Trials

Meet Ionis Pharma’s Newest Collaboration

Why AcelRx Is Jumping Despite FDA Update

Short Sellers Run for Cover From Major Pharma

Short Sellers Back Off Major Biotechs

Mylan’s Mapi Collaboration for Multiple Sclerosis Doesn’t Seem to Be Paying Off

Can This Clinical Hold Stop Affimed’s Momentum?

Akcea Stumbles Over Newest Board Addition

Exelixis Initiates Key Late-Stage Cancer Trial

Major Biopharma Catalysts to Watch For in October

KemPharm: The Secondary Offering From Hell

SI-Bone Announces Potential Pricing for IPO

Why Vaxart’s New Flu Vaccine Is So Great

How a 61-Year-Old Built a $3,500 Monthly Paycheck From Just Two Funds: SCHD and JEPQ

He Worked 20 Years for the Railroad, Then 20 Years Off It. His Social Security Benefit Cut His Railroad Tier I Dollar for Dollar.

‘Your Knowledge of Money and How It Works Is Nil’: Suze Orman to 62-Year-Old Who Nearly Locked His Wife Into $605 a Month

How a 61-Year-Old Built a $3,500 Monthly Paycheck From Just Two Funds: SCHD and JEPQ

He Worked 20 Years for the Railroad, Then 20 Years Off It. His Social Security Benefit Cut His Railroad Tier I Dollar for Dollar.

How a 61-Year-Old Built a $3,500 Monthly Paycheck From Just Two Funds: SCHD and JEPQ

He Worked 20 Years for the Railroad, Then 20 Years Off It. His Social Security Benefit Cut His Railroad Tier I Dollar for Dollar.

Health and Healthcare Articles

All Health and Healthcare Articles

Why Corium Shares Are Booming

How Compugen Is Weathering Thursday’s Storm

CRISPR Wins FDA Approval for Human Trials

Meet Ionis Pharma’s Newest Collaboration

Why AcelRx Is Jumping Despite FDA Update

Short Sellers Run for Cover From Major Pharma

Short Sellers Back Off Major Biotechs

Mylan’s Mapi Collaboration for Multiple Sclerosis Doesn’t Seem to Be Paying Off

Can This Clinical Hold Stop Affimed’s Momentum?

Akcea Stumbles Over Newest Board Addition

Exelixis Initiates Key Late-Stage Cancer Trial

Major Biopharma Catalysts to Watch For in October

KemPharm: The Secondary Offering From Hell

SI-Bone Announces Potential Pricing for IPO

Why Vaxart’s New Flu Vaccine Is So Great

How a 61-Year-Old Built a $3,500 Monthly Paycheck From Just Two Funds: SCHD and JEPQ

He Worked 20 Years for the Railroad, Then 20 Years Off It. His Social Security Benefit Cut His Railroad Tier I Dollar for Dollar.

‘Your Knowledge of Money and How It Works Is Nil’: Suze Orman to 62-Year-Old Who Nearly Locked His Wife Into $605 a Month

Featured Reads

How a 61-Year-Old Built a $3,500 Monthly Paycheck From Just Two Funds: SCHD and JEPQ

He Worked 20 Years for the Railroad, Then 20 Years Off It. His Social Security Benefit Cut His Railroad Tier I Dollar for Dollar.